<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619046</url>
  </required_header>
  <id_info>
    <org_study_id>GreenGeneF_P3</org_study_id>
    <nct_id>NCT01619046</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A</brief_title>
  <official_title>Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlantic Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, efficacy and pharmacokinetics of
      GreenGene™ F in subjects with severe hemophilia A previously treated (&gt; 150 exposure days)
      with a Factor VIII concentrate and without presence or history of inhibitors to FVIII (Factor
      VIII).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subject with development of inhibitors</measure>
    <time_frame>evert 3 months, up to 18 months</time_frame>
    <description>Development of neutralizing antibodies (inhibitors) will be followed during the regular visits, average of 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe the PK profile of GreenGene™ F</measure>
    <time_frame>Pre-dose, 0~48hours post-dose</time_frame>
    <description>AUC, AUMC, Half-life, Incremental recovery, Mean residence time (MRT), Clearance, Volume of distribution - steady state, Cmax, Tmax</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>PK substudy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A cohort of 13-18 subjects will be included in the pharmacokinetic (PK) evaluation of GreenGene™ F and an approved recombinant Factor VIII product (Refacto AF); a minimum of 13 of these subjects will be re-evaluated at study end (50 exposure day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylaxis safety and efficacy substudy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 exposure days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>On-demand safety and efficacy substudy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during 50 exposure days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical substudy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peri-operative hemostatic control of GreenGene™ F in surgery or invasive procedures will be assessed in at least 10 surgeries, some of them major, in at least five subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GreenGene™ F and an approved recombinant Factor VIII product</intervention_name>
    <description>one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate &lt; 10 mL/min</description>
    <arm_group_label>PK substudy</arm_group_label>
    <other_name>GreenGeneF</other_name>
    <other_name>GreenGene F</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GreenGene™ F</intervention_name>
    <description>intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days</description>
    <arm_group_label>Prophylaxis safety and efficacy substudy</arm_group_label>
    <other_name>GreenGeneF</other_name>
    <other_name>GreenGene F</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GreenGene™ F</intervention_name>
    <description>intra-venous infusion,
On-demand safety and efficacy substudy:
minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg</description>
    <arm_group_label>On-demand safety and efficacy substudy</arm_group_label>
    <other_name>GreenGeneF</other_name>
    <other_name>GreenGene F</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GreenGene™ F</intervention_name>
    <description>intra venous infusion,
Surgical substudy:
Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.
Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level.</description>
    <arm_group_label>Surgical substudy</arm_group_label>
    <other_name>GreenGeneF</other_name>
    <other_name>GreenGene F</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects age ≥ 12 years at the time of informed consent

          2. Body weight ≥ 35 kg

          3. Diagnosed with severe hemophilia A. All subjects must have severe hemophilia A with
             baseline FVIII &lt;1% activity; &lt;0.01 IU/mL

          4. Have ≥ 150 previous exposure days to FVIII concentrates, as documented in the
             subject's medical records

          5. Subjects included in the on-demand treatment cohort must have a verifiable record of
             at least three bleeding episodes per month on average in the last 6 months prior to
             enrollment

          6. Negative assays for FVIII inhibitor at inclusion (&lt;0.6BU Nijmegen assay)

          7. Negative assays for FVIII inhibitor in subject files (&lt;0.6BU Nijmegen assay) No
             history of positive inhibitor is allowed

          8. Normal liver and kidney function.

          9. Platelet count ≥ 100,000 μL

         10. Normal prothrombin time or International Normalized Ratio (INR) &lt; 1.5

         11. Subjects receiving therapy for human immunodeficiency virus (HIV) or hepatitis must be
             on a stable treatment regimen

         12. Subjects must be able to withhold FVIII infusions for approximately 72 h prior to each
             FVIII activity and inhibitor assay (96 h if participating in the PK sub study)

         13. Absolute CD4 lymphocyte cell count ≥ 200 μL

         14. Signed the written informed consent form or informed consent was obtained from the
             subject's legal guardian

         15. Females must not be lactating or pregnant at Screening or Baseline (as documented by a
             negative beta-human chorionic gonadotropin [ß hCG] test with a minimum sensitivity of
             25 IU/L or equivalent units of ß hCG). A separate baseline assessment is required if a
             negative screening pregnancy test was obtained more than 72 hours before the first
             dose of study drug

         16. All females will be considered to be of childbearing potential unless they are
             postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age
             group and without other known or suspected cause) or have been sterilized surgically
             (i.e. bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with
             surgery at least one month before dosing)

         17. Willing and able to comply with all aspects of the protocol

        Exclusion Criteria:

          1. Presence at Screening of FVIII inhibitor ≥ 0.6 BU as tested with the Nijmegen
             modification of the Bethesda assay in either central or local laboratory

          2. History of FVIII inhibitor of ≥ 0.6 BU as measured using the Nijmegen modification of
             the Bethesda assay

          3. History of FVIII inhibitor ≥ 1.0 BU if the subject has been tested routinely using the
             original Bethesda assay, or history of periods with low recovery and no response to
             Factor VIII treatment

          4. Demonstrated an inability to respond to conventional doses of FVIII therapy

          5. History of incremental recovery of Factor VIII &lt;1.35% per IU/kg infused

          6. Hematological disorders or blood coagulation diseases (e.g., idiopathic
             thrombocytopenic purpura, von Willebrand disease, etc.) other than hemophilia A

          7. Laboratory or clinical evidence of portal vein hypertension including,(but not limited
             to, an INR &gt; 1.4, the presence of splenomegaly and/or spider angiomata on physical
             examination and/or a history of esophageal hemorrhage or documented esophageal varices

          8. Uncontrolled hypertension (diastolic blood pressure &gt;100 mm Hg)

          9. Hemoglobin &lt; 10 g.dL

         10. HIV disease symptoms regardless of presence of HIV antibodies

         11. Routine administration (or planned routine administration during the course of the
             study), of immunosuppressive or immunomodulating drugs other than antiretroviral
             therapy (e.g., steroids, beta-interferon)

         12. Severe renal dysfunction (creatinine &gt; 2x upper limit of normal [ULN], total bilirubin
             &gt; 2x the ULN)

         13. Liver disease (alanine aminotransferase [ALT], aspartate aminotransferase [ AST] &gt; 3x
             the ULN)

         14. History of diabetes or other metabolic disease

         15. History of hypersensitivity or serious adverse reaction to recombinant or
             plasma-derived FVIII concentrate

         16. History of pretreatment prior to the administration of FVIII products (e.g., of
             antihistamines)

         17. Regular use of antifibrinolytics or medications affecting platelet function

         18. Hypersensitivity to hamster-or mouse derived proteins

         19. Blood transfusions within 30 days of enrollment into the study

         20. Current participation in another investigational drug or device study, or participated
             in a clinical study involving an investigational drug or device within 30 days of
             enrollment into the study

         21. Unable or unwilling to cooperate with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul LeoFrancis Giangrande, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford Haemophilic Centre and Thrombosis Unit, Churchill Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Wait</last_name>
    <phone>540-649-5490</phone>
    <email>kwait@atlanticresearchgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryce Warren</last_name>
      <email>WarrenBryceA@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Kimo Stine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Angeles Orthopaedic Hospital - Hemophilia Treatment Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manny Mangilit</last_name>
      <phone>213-742-1402</phone>
      <email>mannymangilit@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lucy Lacanilao</last_name>
      <phone>213-742-1407</phone>
      <email>LLacanilao@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Doris Quon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbor - UCLA Pediatrics</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Warder</last_name>
      <phone>310-222-3621</phone>
      <email>awarder@labiomed.org</email>
    </contact>
    <contact_backup>
      <last_name>Helen Todoroki</last_name>
      <phone>310-222-4156</phone>
      <email>htodoroki@labiomed.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Lasky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami - Comprehensive Hemophilia Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Ibarra</last_name>
      <phone>305-243-5343</phone>
      <email>cibarra@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cecilia Prado</last_name>
      <phone>305-243-6925</phone>
      <email>cprado@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joanna Davis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Boise Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammie Eslinger</last_name>
      <phone>208-381-2774</phone>
      <email>eslinget@slhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Tim Honeycutt</last_name>
      <phone>208-381-5357</phone>
      <email>honeycut@slhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Eugenia Chang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Boyce</last_name>
      <phone>312-942-0243</phone>
      <email>kristin_boyce@rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rosie Howard</last_name>
      <phone>312-942-7902</phone>
      <email>Rosie_Howard@rush.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lisa Boggio, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan State University Center for Bleeding Disorders &amp; Clotting Disorders</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48823</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Adkins</last_name>
      <phone>517-353-9385</phone>
      <email>sue.adkins@hc.msu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hillary Witkop</last_name>
      <phone>517-353-9385</phone>
      <email>witkophi@msu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Penner, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital - Kansas City Regional Hemophilia Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Streeter</last_name>
      <phone>816-234-3502</phone>
      <email>sstreeter@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Wicklund, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center - Hemophilia Treatment Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Murray</last_name>
      <phone>718-470-7380</phone>
      <email>Pmurray1@nshs.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Patriarca</last_name>
      <phone>718-470-7380</phone>
      <email>lpatriar@nshs.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Lipton, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Beach</last_name>
      <phone>503-494-7425</phone>
      <email>beachk@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alysia Cox</last_name>
      <phone>503-494-5109</phone>
      <email>coxal@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Recht, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devereux Hannah</last_name>
      <phone>+1 780 782 4731</phone>
      <email>hannah.devereux@biosample.ca</email>
    </contact>
    <investigator>
      <last_name>Bruce Ritchie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nagel Kim</last_name>
      <email>NAGEL@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Anthony Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Associates, Ltd.</name>
      <address>
        <city>Christchurch</city>
        <zip>8081</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Lauren</last_name>
      <phone>+64 3 364 0386</phone>
      <email>carolyn.lauren@cdhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>Mark Smith, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marcin Pasiarski, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>wojewodzki szpital Specjalistyczny, klinika hematologii uniwersytetu medycznego w łodzi</name>
      <address>
        <city>Łodzi</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Krzysztof Chojnowski, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnaul Altai State Scientfic Center</name>
      <address>
        <city>Barnaul</city>
        <zip>4656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>A Mamaev, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kirov Research Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>M Timofeeva, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ismailov City Children's Clinical Hospital of Board of Health of Moscow City</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vladimir Vdovin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budget Educational Institution of Higher professional Education &quot;Samara State Medical University&quot; of the Ministry of Health and Social Process of the Russian Federation</name>
      <address>
        <city>Samara</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Igor Davydkin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ufa Republican Clinical Hospital</name>
      <address>
        <city>Ufa</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>G Gaysarova, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dnepropetrovsk City Clinical Hospital</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Y Shinkarenko, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Urgent and Reconstructive surgery named after V.K. Gusak of National Academy of Medical Sciences of Ukraine</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ekaterina Vilchevska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kharkov Regional Clinical Oncology Center</name>
      <address>
        <city>Kharkov</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tetyana Poposvka, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital No 91</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ievgenii Averianov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Blood Pathology and Transfusion Medicine of National Academy of Medical Sciences of Ukraine Department of Surgery and Clinical Transfusiology</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oleksandra Stasyshyn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhya Region Clinical Child Hospital</name>
      <address>
        <city>Zaporzhye</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>A Borodin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital, Department of Haematology</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Mills</last_name>
      <phone>01872 252527</phone>
      <email>bianca.mills@rcht.cornwall.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Desmond Creagh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hull Haemophillia Centre, Hull Royal Infirmary</name>
      <address>
        <city>Humberside</city>
        <state>Hull</state>
        <zip>HU3 2JZ HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Armitage</last_name>
      <phone>01482 461254</phone>
      <email>lisa.armitage@hey.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David Allsup, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Foulkes Matt</last_name>
      <phone>+44 (0)161 901 4565</phone>
      <email>Matt.Foulkes@cmft.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Davies Carolyn</last_name>
      <phone>+44 (0)161 701 4353</phone>
      <email>clinical.trials@cmft.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Hay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>Westminster</city>
        <state>London</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa Aradom</last_name>
      <phone>020-7188-2781</phone>
      <email>elsa.aradom@gstt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Sheela Medahunsi</last_name>
      <phone>020-7188-2808</phone>
      <email>Sheela.Medahunsi@gstt.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Graeme Thomson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Hampshire Haemophilia Centre</name>
      <address>
        <city>Basingstoke</city>
        <state>North Hampshire</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Watson</last_name>
      <phone>01256 314793</phone>
      <email>yvonne.watson@hhft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Savita Rangarajan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Liverpool</name>
      <address>
        <city>Liverpool</city>
        <zip>L69 3GA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Kay-Jones</last_name>
      <phone>+44(0)151 706 4329</phone>
      <email>clare.kay-jones@rlbuht.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Jayne Keaney</last_name>
      <phone>+44(0)151 706 4329</phone>
      <email>jayne.keaney@rlbuht.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Tina Dutt, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital, Haemophilia Centre &amp; Thrombosis Unit</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pratima Chowdary, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital, Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Fletcher</last_name>
      <phone>+44 1865 225316</phone>
      <email>Simon.Fletcher@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Paul Giangrande, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2012</study_first_posted>
  <last_update_submitted>July 2, 2014</last_update_submitted>
  <last_update_submitted_qc>July 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GreenGene™F, Previously Treated Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

